These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8767361)

  • 1. Examination of the biological safety of a drug derived from mammalian organs.
    Hübner GE; Koch RC; Sprenger KB; Stadler PJ; Gölker CF
    Arzneimittelforschung; 1996 Jun; 46(6):657-61. PubMed ID: 8767361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol.
    Gölker CF; Whiteman MD; Gugel KH; Gilles R; Stadler P; Kovatch RM; Lister D; Wisher MH; Calcagni C; Hübner GE
    Biologicals; 1996 Jun; 24(2):103-11. PubMed ID: 8889056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents.
    Dev Biol Stand; 1998; 93():133-4. PubMed ID: 9737391
    [No Abstract]   [Full Text] [Related]  

  • 6. Validation of removal of human retroviruses.
    Marcus-Sekura CJ
    Dev Biol Stand; 1991; 75():133-43. PubMed ID: 1794615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE).
    Rohwer RG
    Dev Biol Stand; 1996; 88():247-56. PubMed ID: 9119146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on bovine spongiform encephacitis and current status of safety control of medical devices deriving from animals].
    Shi X; Tan F; Wang Z
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Nov; 20(11):1138-44. PubMed ID: 17191585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antemortem identification of bovine spongiform encephalopathy from serum using infrared spectroscopy.
    Lasch P; Schmitt J; Beekes M; Udelhoven T; Eiden M; Fabian H; Petrich W; Naumann D
    Anal Chem; 2003 Dec; 75(23):6673-8. PubMed ID: 14640744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment and surveillance for bovine spongiform encephalopathy.
    Heim D; Gardner I; Mumford E; Kihm U
    Rev Sci Tech; 2006 Dec; 25(3):937-50. PubMed ID: 17361761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein purification: aspects of processes for pharmaceutical products.
    Berthold W; Walter J
    Biologicals; 1994 Jun; 22(2):135-50. PubMed ID: 7917230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Process scale considerations in evaluation studies and scale-up.
    Walter JK; Werz W; Berthold W
    Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Animal-derived feeds as possible vectors for bovine spongiform encephalopathy (BSE) in Germany. 1. Comparative risk assessment for a single animal food of animal origin].
    Kamphues J; Zentek J; Oberthür RC; Flachowsky G; Coenen M
    Dtsch Tierarztl Wochenschr; 2001 Jul; 108(7):283-90. PubMed ID: 11505845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral validation design of a manufacturing process.
    Larzul D
    Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinion of the EMEA on the potential risk associated with medicinal products in relation to bovine spongiform encephalopathy (BSE) (16 April 1996) and report from the Committee for Proprietary Medicinal Products (CPMP) on the 'Note for Guidance on minimizing the risk of transmitting animal spongiform encephalopathies via medicinal products' (15 April 1997).
    Adverse Drug React Toxicol Rev; 1997 Jun; 16(2):113-21. PubMed ID: 9359933
    [No Abstract]   [Full Text] [Related]  

  • 19. [Meat and potential risks].
    Gareis M
    Dtsch Tierarztl Wochenschr; 2002 Aug; 109(8):345-8. PubMed ID: 12224462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses.
    Pocchiari M
    Dev Biol Stand; 1991; 75():87-95. PubMed ID: 1794633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.